quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:32:22·28d
SECFiling
Inhibikase Therapeutics Inc. logo

SEC Form 10-K filed by Inhibikase Therapeutics Inc.

IKT· Inhibikase Therapeutics Inc.
Health Care
Full content unavailable. See the original source below.
Original source

Companies

  • IKT
    Inhibikase Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Mar 4UpdateLadenburg Thalmann$4.00
  • Jan 21UpdateBofA Securities$6.00
  • Dec 26UpdateH.C. Wainwright$8.00
  • Dec 11UpdateCantor Fitzgerald$4.00
  • Feb 12UpdateH.C. Wainwright-
  • Jul 15UpdateJonesTrading$12.00

Related

  • SEC3d
    SEC Form PRE 14A filed by Inhibikase Therapeutics Inc.
  • SEC17d
    Inhibikase Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure
  • PR17d
    Inhibikase Therapeutics Announces Enrollment of First Patient in IMPROVE-PAH Global Phase 3 Study of IKT-001 in the Treatment of Pulmonary Arterial Hypertension
  • PR20d
    Inhibikase Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  • SEC28d
    SEC Form S-8 filed by Inhibikase Therapeutics Inc.
  • SEC28d
    SEC Form 8-K filed by Inhibikase Therapeutics Inc.
  • PR28d
    Inhibikase Therapeutics Announces Full Year 2025 Financial Results and Highlights Recent Activity
  • ANALYST51d
    Ladenburg Thalmann initiated coverage on Inhibikase Therapeutics with a new price target
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022